News

Tuesday 30th May 2023

The CRISTAL Index: Improving the assessment of new scleroderma treatments in clinical trials

One of SRUK’s central objectives is to advance research that will lead to the development of new and effective treatments. But how do we make sure that new therapies will be effective? Recently, SRUK has funded a US-based research project that will help to ensure that potential treatments are effective in ways that are relevant to both patients and clinicians. This could be vital in giving people living with the condition access to treatments that work for them.

Read Article

Wednesday 10th May 2023

Imperial College London's 'Science in Medicine School Teams Prize 2023' now open for entries!

The Scleroderma and Raynaud’s UK sponsored 'Science in Medicine School Teams Prize 2023' contest is now open for entries. The contest aims to engage sixth form school students with science in medicine, and challenges students to prepare an ePoster with a novel vision on how to promote the health and well-being of individuals with Scleroderma and/or Raynaud’s. If you're interested in entering, or know someone in sixth form who might be, read on to find out more!

Read Article

Thursday 26th May 2022

Getting a Grip on Scleroderma: Double Hand Transplant for Scleroderma Patient

A British man has become the first Scleroderma patient to receive a double hand transplant for the condition, giving him a new lease of life and prompting hope for many of those most severely affected by the condition.

Read Article

Tuesday 10th May 2022

The VEDOSS Project – Predicting the Progression of Raynaud’s to Systemic Sclerosis

New research suggests the ‘VEDOSS’ Criteria could be used to accurately predict which individuals living with Raynaud's are likely to progress to Systemic Sclerosis, prompting further hope regarding the early detection and treatment of the condition.

Read Article

Thursday 20th May 2021

Celebrating World Clinical Trials Day!

20 May 2021 is World Clinical Trials Day to mark the anniversary of the first-ever trial that was conducted in 1747. Today, clinical trials are vital in determining the safety and efficacy of new treatments all over the world. But what happens in a clinical trial, and could you take part?

Read Article

Friday 14th May 2021

Your Raynaud’s and You – Insights from SRUK’s work on the Raynaud’s App

Can you imagine a world where we could have a greater understanding of Raynaud’s? Have more information on what triggers an attack? Understand how in some cases Raynaud’s combined with other symptoms may be an early predictor of scleroderma? The Raynaud’s ResearchApp, an SRUK-led partnership with app development company Healthbit and data company D4T4, intends to do just this!

Read Article

Friday 7th May 2021

The Raynaud’s App: the story so far

SRUK is pioneering ‘The Raynaud’s ResearchApp,’ that aims to help identify Raynaud’s patients at risk of developing scleroderma, with a view to achieving earlier diagnosis and improved outcomes. The technology also enables users to record their experiences of Raynaud’s symptoms and learn more about potential triggers. The App has recently been piloted in a clinical trial.

Read Article

Thursday 28th May 2020

Growing up with juvenile scleroderma

What is it really like to grow up with scleroderma? We look at the various ways that this condition can affect our children, both physically and emotionally, as they navigate the path to adulthood.

Read Article

Thursday 28th May 2020

Chronic pain – how to break the cycle and take control

With around 28 million adults now living with chronic pain in the UK, it has become something of a silent epidemic. There are however a number of ways to help reduce its impact upon your life.

Read Article

Friday 31st May 2019

New internal regulator of the immune system discovered in an SRUK-funded study

SRUK are thrilled to see the results of an investigation, undertaken by an international team of researchers and clinicians, where there has been the identification of a new internal regulator which helps to control the body’s immune response.

Read Article